Denis Chem Lab
BSE: DENISCHEM · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Denis Chem Lab's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Denis Chem Lab Limited is an Ahmedabad-based pharmaceutical company specialising in the manufacture of sterile intravenous fluids and pharmaceutical formulations. The company operates a modern facility in Chhatral, producing life-saving infusions such as dextrose, sodium chloride, and electrolyte solutions for clinical use.
Business Model
The company generates revenue by manufacturing and supplying large volume parenterals to hospitals and clinical settings within India and international export markets. It leverages its specialised production capabilities to maintain a position within the healthcare infrastructure supply chain.
Growth Outlook
Growth is driven by the company's focus on the niche intravenous therapy segment and its ability to meet international quality standards for pharmaceutical formulations. Continued demand for essential hospital supplies remains a key factor in its operational strategy.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining international quality standards and potential audits by health authorities.
- Market Competition. Intense competition in the pharmaceutical sector may exert pressure on pricing and profit margins for intravenous fluids.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials for sterile manufacturing could impact production efficiency.
- Export Dependency. Exposure to international markets introduces risks associated with geopolitical instability and currency exchange rate fluctuations.
Start your research today
Unlock AI insights, financials, peers and live data on Denis Chem Lab and 5,000+ companies — free.
Key Metrics
REVENUE
₹182 Cr
TTM · standalone
NET PROFIT
₹8 Cr
TTM · standalone
EPS
₹6.06
TTM · standalone
RETURN ON EQUITY
9.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
14.5%
TTM · standalone
P/E
11.1x
Q4 FY26 · standalone
EV/EBITDA
5.1x
Q4 FY26 · standalone
EBITDA MARGIN
10.8%
TTM · standalone
NET PROFIT MARGIN
0.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Denis Chem LabDENISCHEM | ₹96 Cr | 11.12 | 5.09 | 4.9% | 10.8% | 9.7% | 14.5% | -28.7% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Denis Chem Lab
BSE: DENISCHEM · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Denis Chem Lab's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Denis Chem Lab Limited is an Ahmedabad-based pharmaceutical company specialising in the manufacture of sterile intravenous fluids and pharmaceutical formulations. The company operates a modern facility in Chhatral, producing life-saving infusions such as dextrose, sodium chloride, and electrolyte solutions for clinical use.
Business Model
The company generates revenue by manufacturing and supplying large volume parenterals to hospitals and clinical settings within India and international export markets. It leverages its specialised production capabilities to maintain a position within the healthcare infrastructure supply chain.
Growth Outlook
Growth is driven by the company's focus on the niche intravenous therapy segment and its ability to meet international quality standards for pharmaceutical formulations. Continued demand for essential hospital supplies remains a key factor in its operational strategy.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining international quality standards and potential audits by health authorities.
- Market Competition. Intense competition in the pharmaceutical sector may exert pressure on pricing and profit margins for intravenous fluids.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials for sterile manufacturing could impact production efficiency.
- Export Dependency. Exposure to international markets introduces risks associated with geopolitical instability and currency exchange rate fluctuations.
Start your research today
Unlock AI insights, financials, peers and live data on Denis Chem Lab and 5,000+ companies — free.
Key Metrics
REVENUE
₹182 Cr
TTM · standalone
NET PROFIT
₹8 Cr
TTM · standalone
EPS
₹6.06
TTM · standalone
RETURN ON EQUITY
9.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
14.5%
TTM · standalone
P/E
11.1x
Q4 FY26 · standalone
EV/EBITDA
5.1x
Q4 FY26 · standalone
EBITDA MARGIN
10.8%
TTM · standalone
NET PROFIT MARGIN
0.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26